HER2 Status in Gastro-Oesophageal Adenocarcinomas
Author Information
Author(s): James E Boers, Harriëtte Methorst, Natalie Meeuwissen
Primary Institution: Isala klinieken
Hypothesis
The study aims to compare HER2 status in gastro-oesophageal adenocarcinomas using different testing methods.
Conclusion
HER2-positivity is present in a significant proportion of oesophago-gastric adenocarcinomas, with higher sensitivity for amplification using the 4B5 antibody compared to SP3.
Supporting Evidence
- HER2 gene amplification was detected in 10-20% of gastric adenocarcinomas.
- Sensitivity of SP3-IHC-positivity and 4B5-IHC-positivity for amplification was 77% and 96%, respectively.
- Amplification was heterogeneous in 73% of the adenocarcinomas.
- 24% of oesophago-gastric carcinomas and 7% of distal stomach tumours were HER2 amplified.
Takeaway
This study looked at how many stomach and esophagus cancers have a specific marker called HER2, which can help doctors decide on treatments.
Methodology
The study used immunohistochemistry and in situ hybridization on biopsy specimens from patients with adenocarcinomas of the oesophagus and stomach.
Limitations
The study was conducted at a single institution and may not represent broader populations.
Participant Demographics
The study included 178 consecutive patients diagnosed with adenocarcinoma of the stomach or distal oesophagus.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website